{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:16:31Z","timestamp":1791494191709,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd008996","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000}}],"reference-count":96,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008996.pub2","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:20:02Z","timestamp":1488327602000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Eplerenone for hypertension"],"prefix":"10.1002","volume":"2017","author":[{"given":"Tina SC","family":"Tam","sequence":"first","affiliation":[{"name":"Lower Mainland Pharmacy Services; Pharmacy; Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May HY","family":"Wu","sequence":"additional","affiliation":[{"name":"Lower Mainland Pharmacy Services; Surrey Memorial Hospital Pharmacy; Surrey BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C","family":"Masson","sequence":"additional","affiliation":[{"name":"Fraser Health Authority; Pharmacy Services; 3938 Kincaid St Burnaby BC Canada V5G 1V7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P","family":"Tsang","sequence":"additional","affiliation":[{"name":"Fraser Health Authority; Pharmacy Services; 32900 Marshall Road Abbotsford BC Canada V2S 0C2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah N","family":"Stabler","sequence":"additional","affiliation":[{"name":"Lower Mainland Pharmacy Services; Cardiac Clinics, Royal Columbian Hospital; Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus","family":"Kinkade","sequence":"additional","affiliation":[{"name":"Lower Mainland Pharmacy Services; Pharmacy; Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Tung","sequence":"additional","affiliation":[{"name":"Lower Mainland Pharmacy Services; Pharmacy; Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M","family":"Tejani","sequence":"additional","affiliation":[{"name":"University of British Columbia; Therapeutics Initiative; 2176 Health Sciences Mall Vancouver BC Canada V6T 1Z3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"issue":"18","key":"10.1002\/14651858.CD008996.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD008996.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD008996.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"175-83; quiz 18","DOI":"10.1111\/j.1524-6175.2004.03146.x","article-title":"Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"6","author":"Saruta","year":"2004","journal-title":"Journal of Clinical Hypertension (Greenwich)"},{"issue":"8","key":"10.1002\/14651858.CD008996.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"American Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008996.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"624-9; discussi","DOI":"10.1097\/HJH.0b013e32835d6d49","article-title":"Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism","volume":"31","author":"Amar","year":"2013","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD008996.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/hr.2010.46","article-title":"Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria","volume":"33","author":"Ando","year":"2010","journal-title":"Hypertension Research"},{"issue":"12","key":"10.1002\/14651858.CD008996.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/s2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD008996.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/S2213-8587(15)00055-8","article-title":"Correction to Antialbuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo controlled trial [Lancet Diabetes Endocrinol, 2, (2014) 944-953]","volume":"3","author":"Ando","year":"2015","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD008996.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/MAJ.0b013e31819b3a80","article-title":"New therapeutic options in patients prone to hypertension: a focus on direct Renin inhibition and aldosterone blockade.","volume":"337","author":"Basile","year":"2009","journal-title":"The American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1681\/ASN.2014030293","article-title":"Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome","volume":"26","author":"Blanchard","year":"2015","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"2","key":"10.1002\/14651858.CD008996.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/107424840501000202","article-title":"Pharmacotherapy of congestive heart failure in elderly patients","volume":"10","author":"Burger","year":"2005","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD008996.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clinical Therapy"},{"issue":"6","key":"10.1002\/14651858.CD008996.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"Journal of the American Society of Hypertension"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0015|cit15","unstructured":"The Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Eplerenone for the treatment of hypertension Emerging Drug List 2003 1 3"},{"issue":"2","key":"10.1002\/14651858.CD008996.pub2-BIB0016|cit16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008117.pub2","article-title":"Pharmacological interventions for hypertension in children","author":"Chaturvedi","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1753-0407.2011.00122.x","article-title":"Effect of acute mineralocorticoid receptor blockade on flow-mediated dilation in middle aged and older adults with metabolic syndrome","volume":"3","author":"Christou","year":"2011","journal-title":"Journal of Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008996.pub2-BIB0018|cit18","first-page":"A13","article-title":"Mineralocorticoid receptor blockade does not result in arterial destiffening in healthy older adults","volume":"60","author":"Christou","year":"2012","journal-title":"Hypertension"},{"issue":"6-7","key":"10.1002\/14651858.CD008996.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ejheart.2007.04.004","article-title":"Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet","volume":"9","author":"Cleland","year":"2007","journal-title":"European Journal of Heart Failure"},{"issue":"36","key":"10.1002\/14651858.CD008996.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/eurheartj\/eht247","article-title":"The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial","volume":"34","author":"Collier","year":"2013","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD008996.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/clc.4960260502","article-title":"Aldosterone antagonism and hypertension","volume":"26","author":"Conti","year":"2003","journal-title":"Clinical Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD008996.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies","volume":"28","author":"Dahal","year":"2015","journal-title":"American Journal of Hypertension"},{"issue":"11","key":"10.1002\/14651858.CD008996.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1016\/S0149-2918(03)80326-0","article-title":"The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist","volume":"25","author":"Davis","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD008996.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF03366066","article-title":"Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system","volume":"152","author":"Derer","year":"2010","journal-title":"MMW Fortschritte der Medizin"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.cardfail.2010.06.026","article-title":"Randomized trial of aldosterone AntagonisM in diastolic heart failure (RAAM-DHF)","volume":"1","author":"Deswal","year":"2010","journal-title":"Journal of Cardiac Failure"},{"issue":"8","key":"10.1002\/14651858.CD008996.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"Journal of Cardiac Failure"},{"issue":"6","key":"10.1002\/14651858.CD008996.pub2-BIB0027|cit27","first-page":"97","article-title":"Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure","volume":"31","author":"Dieterich","year":"2005","journal-title":"Fiziol Cheloveka"},{"issue":"4","key":"10.1002\/14651858.CD008996.pub2-BIB0028|cit28","first-page":"271","article-title":"A New Face of Aldosterone","volume":"7","author":"Dobrucki","year":"2003","journal-title":"Nadcisnienie Tetnicze"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008996.pub2-BIB0029|cit29","first-page":"322A","article-title":"Eplerenone, a new selective aldosterone receptor antagonist (SARA): efficacy in patients with mild to moderate hypertension [Abstract]","volume":"9","author":"Epstein","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD008996.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","article-title":"Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria [Abstract no: OR54]","volume":"15","author":"Epstein","year":"2002","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"S222","DOI":"10.1093\/eurjhf\/hst009","article-title":"Mineralocorticoid receptor antagonism in patients with coronary artery disease and preserved ejection fraction-a randomized, double-blind trial","volume":"12","author":"Flammer","year":"2013","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11892-005-0065-5","article-title":"ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure","volume":"5","author":"Funder","year":"2005","journal-title":"Current Diabetes Reports"},{"issue":"6","key":"10.1002\/14651858.CD008996.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/hr.2010.71","article-title":"Eplerenone in chronic renal disease: the EVALUATE trial","volume":"33","author":"Funder","year":"2010","journal-title":"Hypertens Res"},{"issue":"4","key":"10.1002\/14651858.CD008996.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11906-000-0041-z","article-title":"The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure","volume":"2","author":"Hameedi","year":"2000","journal-title":"Current Hypertension Reports"},{"issue":"13","key":"10.1002\/14651858.CD008996.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archinte.163.13.1543","article-title":"Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension","volume":"163","author":"Hollenberg","year":"2003","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0038|cit38","first-page":"Abstract no: 82","article-title":"Mineralocorticoid receptor blockade does not improve vascular endothelial function in older adults with metabolic syndrome [Abstract]","volume":"25","author":"Hwang","year":"2011","journal-title":"FASEB Journal"},{"issue":"8","key":"10.1002\/14651858.CD008996.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.exger.2013.05.058","article-title":"Role of mineralocorticoid receptors in arterial stiffness in human aging","volume":"48","author":"Hwang","year":"2013","journal-title":"Experimental Gerontology"},{"issue":"5","key":"10.1002\/14651858.CD008996.pub2-BIB0040|cit40","first-page":"220","article-title":"Aldosterone-to-renin ratio as a screening test for primary aldosteronism--the Dutch ARRAT Study","volume":"66","author":"Jansen","year":"2008","journal-title":"Netherlands Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008996.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD008996.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/clc.20442","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"32","author":"Karagiannis","year":"2009","journal-title":"Clinical Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008996.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"Journal of Clinical Hypertension (Greenwich)"},{"issue":"2","key":"10.1002\/14651858.CD008996.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD008996.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2003-032149","article-title":"Distinguishing the antihypertensive and electrolyte effects of eplerenone","volume":"89","author":"Levy","year":"2004","journal-title":"Journal of Clinical and Endocrinology Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD008996.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jpeds.2010.02.042","article-title":"The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study","volume":"157","author":"Li","year":"2010","journal-title":"Journal of Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD008996.pub2-BIB0047|cit47","first-page":"853","article-title":"New developments in the management of hypertension","volume":"68","author":"Magill","year":"2003","journal-title":"American Family Physician"},{"issue":"3","key":"10.1002\/14651858.CD008996.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11906-005-0012-5","article-title":"Aldosterone receptor antagonists: biology and novel therapeutic applications","volume":"7","author":"Magni","year":"2005","journal-title":"Current Hypertension Reports"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0049|cit49","first-page":"52","article-title":"Aldosterone antagonists in hypertension and heart failure","volume":"61","author":"Mantero","year":"2000","journal-title":"Annales d'endocrinologie"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0051|cit51","unstructured":"Pfizer Peds I (Pediatric Eplerenone Development Study I): a randomized, double-blind, placebo withdrawal, parallel group, dose-response study to evaluate the efficacy and safety of eplerenone In the treatment of hypertension in children ClinicalTrials.gov 2008"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0052|cit52","unstructured":"Pfizer Peds II (Pediatric Eplerenone Development Study II)--An open label, long-term study to evaluate the safety of eplerenone in the treatment of hypertension in children ClinicalTrials.gov 2004"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0053|cit53","unstructured":"Pfizer A study to evaluate the efficacy of eplerenone compared with losartan for the treatment of patients with mild to moderate hypertension ClinicalTrials.gov 2009"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0054|cit54","unstructured":"Novartis A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699, a new experimental antihypertensive drug, in patients with essential hypertension ClinicalTrials.gov 2012"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0055|cit55","unstructured":"Novartis A study to evaluate the effects of LCI699 on safety and efficacy in subjects with resistant hypertension receiving combination therapy with three or more antihypertensive drugs, including a diuretic ClinicalTrials.gov 2012"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0056|cit56","unstructured":"Wofford M University of Mississippi Medical Center A study of the effects of eplerenone and amlodipine on blood pressure and basal metabolic rate in obese hypertensives ClinicalTrials.gov 2014"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0057|cit57","unstructured":"Holmberg MJ Creighton University Aldosterone blockade to prevent myocardial remodeling in patients with controlled essential hypertension ClinicalTrials.gov 2014"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0058|cit58","unstructured":"Washington University School of Medicine A randomized, double blind pilot study evaluating CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) polymorphism effects on hypertrophy regression in caucasian hypertensive patients treated with eplerenone ClinicalTrials.gov 2015"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0059|cit59","unstructured":"Novartis LFF269 compared to placebo after treatment in subjects with essential hypertension ClinicalTrials.gov 2012"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0060|cit60","unstructured":"Daiichi Sankyo Inc A study to evaluate efficacy and safety of CS-3150 in Japanese hypertensive subjects ClinicalTrials.gov 2016"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijcard.2014.09.091","article-title":"Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis","volume":"177","author":"Pelliccia","year":"2014","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2014.10.150","article-title":"Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension","volume":"200","author":"Pelliccia","year":"2015","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"16-7; discussio","DOI":"10.1016\/j.ebcm.2003.12.012","article-title":"Trial suggests that combining eplerenone and enalapril reduces left ventricular hypertrophy in hypertension more effectively than either treatment alone","volume":"8","author":"Pitt","year":"2004","journal-title":"Evidence-based Cardiovascular Medicine"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"A65","DOI":"10.1111\/j.1751-7176.2011.00459.x","article-title":"Hyperkalemia with aldosterone antagonist monotherapy in essential hypertension. A meta-analysis","volume":"1","author":"Romero","year":"2011","journal-title":"Journal of Clinical Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/HJH.0000000000000762","article-title":"Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses","volume":"34","author":"Roush","year":"2016","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD008996.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1161\/01.HYP.0000359702.48610.72","article-title":"MR blockade improves cardiac and vascular target organ damage independent of blood pressure in resistant hypertension [Abstract]","volume":"54","author":"Schmidt","year":"2009","journal-title":"Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD008996.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1527-3466.2003.tb00114.x","article-title":"Eplerenone: a selective aldosterone blocker","volume":"21","author":"Stier","year":"2003","journal-title":"Cardiovascular Drug Review"},{"issue":"4","key":"10.1002\/14651858.CD008996.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clinical Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2337\/diaspect.19.1.25","article-title":"Management of hypertension in diabetes","volume":"19","author":"Stults","year":"2006","journal-title":"Diabetes Spectrum"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1472-6823-12-19","article-title":"Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial","volume":"12","author":"Tomaschitz","year":"2012","journal-title":"BMC Endocrine Disorders"},{"issue":"5","key":"10.1002\/14651858.CD008996.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/MNH.0b013e32833ce6d5","article-title":"Aldosterone blockade in chronic kidney disease: can it improve outcomes?","volume":"19","author":"Toto","year":"2010","journal-title":"Current Opinion in Nephrology and Hypertension"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0072|cit72","unstructured":"U.S. Food Drug Administration Clinical review: detailed study reviews section Drug approvals and databases"},{"issue":"6","key":"10.1002\/14651858.CD008996.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/ndt\/16.6.1095","article-title":"Drug treatment of isolated systolic hypertension","volume":"16","author":"Zwieten","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD008996.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1067\/mhj.2002.129970","article-title":"Clinical implications of aldosterone blockade","volume":"144","author":"Weber","year":"2002","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD008996.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2165\/00003495-200868030-00006","article-title":"Drugs for cardiovascular disease prevention in women: Implications of the AHA guidelines - 2007 Update","volume":"68","author":"Wenger","year":"2008","journal-title":"Drugs"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD008996.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"A61.E582","DOI":"10.1016\/S0735-1097%2810%2960583-9","article-title":"Blockade of aldosterone production as a novel approach to the management of high blood pressure: efficacy and tolerability of the aldosterone synthase inhibitor LCI699 in patients with stage 1-2 hypertension [Abstract]","volume":"55","author":"White","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD008996.pub2-BIB0077|cit77","first-page":"lb480","article-title":"Mineralocorticoid receptor blockade does not affect arterial compliance in middle-aged and older adults with and without metabolic syndrome","volume":"25","author":"Yoo","year":"2011","journal-title":"FASEB Journal"},{"issue":"3","key":"10.1002\/14651858.CD008996.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004349.pub2","article-title":"Treatment blood pressure targets for hypertension","author":"Arguedas","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijcard.2014.07.067","article-title":"Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication","volume":"176","author":"Banach","year":"2014","journal-title":"International Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD008996.pub2-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008169.pub2","article-title":"Spironolactone for hypertension","author":"Batterink","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cjca.2015.02.016","article-title":"The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"31","author":"Canadian Hypertension Education Program (CHEP)","year":"2015","journal-title":"Canadian Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD008996.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006742.pub2","article-title":"Pharmacotherapy for mild hypertension","author":"Diao","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0083|cit83","volume-title":"Pharmacotherapy: A Pathophysiologic Approach","author":"DiPiro","year":"2014"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0084|cit84","unstructured":"Inspra Compendium of pharmaceuticals and specialties, online version (e-CPS) www.e-therapeutics.ca\/cps.select.preliminaryFilter.action?simplePreliminaryFilter=eplerenone#m701861n00006"},{"issue":"4","key":"10.1002\/14651858.CD008996.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003823.pub2","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","author":"Heran","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension","volume":"27","author":"Jansen","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"19","key":"10.1002\/14651858.CD008996.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0088|cit88","volume-title":"Basic and Clinical Pharmacology","author":"Katzung","year":"2012"},{"issue":"9349","key":"10.1002\/14651858.CD008996.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"1903-13 [Erratu","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008996.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1517\/17425250902837973","article-title":"The clinical pharmacology of eplerenone","volume":"5","author":"Muldowney","year":"2009","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"5","key":"10.1002\/14651858.CD008996.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"e5673","DOI":"10.1371\/journal.pone.0005673","article-title":"Factors affecting blood pressure variability: lessons learned from two systematic reviews of randomized controlled trials","volume":"4","author":"Musini","year":"2009","journal-title":"PLOS ONE"},{"key":"10.1002\/14651858.CD008996.pub2-BIB0092|cit92","volume-title":"Hypertension: The Clinical Management of Primary Hypertension in Adults","author":"National Clinical Guideline Centre (UK)","year":"2011"},{"issue":"2","key":"10.1002\/14651858.CD008996.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.hjh.0000200513.48441.8e","article-title":"In a population-based prospective study, no association between high blood pressure and mortality after age 85 years","volume":"24","author":"Bemmel","year":"2006","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000000065","article-title":"Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension","volume":"32","author":"Weber","year":"2014","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD008996.pub2-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub5","article-title":"Beta-blockers for hypertension","author":"Wiysonge","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008996.pub2-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001841.pub2","article-title":"First-line drugs for hypertension","author":"Wright","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008996.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T02:03:40Z","timestamp":1679969020000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008996.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hypertension Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":96,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008996.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]}}}